HIGH PERFORMANCE LIQUID CHROMATOGRAPHY MOBILE PHASE

Abstract: There is described a mobile phase for use in the purification of proteins using reversed phase HPLC on a preparative scale. The mobile phase is an aqueous solution containing .005 to 1M of a physiologically acceptable acid of the general formula YCOOH where Y is a polar electron withdrawing group capable of hydrogen bonding silanol groups. The solution also contains up to 95% V of a physiologically acceptable organic solvent. A preparative method of purifying proteins such as HSA or BSA using reversed phase HPLC is also described.

Description: This invention relates to high performance liquid chromatography (HPLC). More particularly it relates to a mobile phase for use in reversed phase HPLC which is particularly suitable for the recovery of proteins. HPLC is established as an efficient tool in both analytical and preparative techniques for the recovery of biological products in high purity. Reversed phase HPLC with bonded supports (such as C₁₈-silica) is optimal for highly polar solutes. Reversed phase HPLC generally involves the use of a polar eluent with a non-polar support. Highly polar solutes have a greater affinity for the eluent than does the support and solutes are eluted in reverse order of polarity. High molecular weight biological molecules such as proteins have a complex three dimensional structure which must be preserved to maintain the biological function of the sample. In a reversed phase chromatographic separation the optimal separation involves the interaction between the hydrocabonaceous groups of the support and hydrophobic surface features on the protein molecule. The resolution of a protein mixture on a hydrophobic column is therefore related to specific topological features of the individual protein species, with the components of lower or less accessible hydrophobic surface patches being eluted first. Because of this separation mechanism HPLC is a highly resolutive chromatographic method. Even slight compositional differences between proteins will lead to topological differences which can result in an effective separation. For example, porcine and human insulin are easily separated by HPLC, although the two molecules only have a minor difference in a single amino acid residue. Hydrophobic interactions between a target protein molecule and the reversed phase column must be carefully controlled. If the protein molecule is significantly destabilised in the chromatographic medium, unfolding of the three dimensional structure of the protein molecule can expose buried hydrophobic groups which can lead to additional hydrophobic interactions with the reversed phase column and prevent elution of the protein. Such increased interactions between the solute and stationary phase can lead to denaturation of the protein molecule and/or low recoveries due to irreversible multisite binding of the solute. Currently used mobile phases often destabilise the protein sample and thus do not allow for high yield preparative separations. In addition solvents such as acetonitrile are widely used to elute polypeptide samples that are retained by reversed phase columns. Such solvents are highly toxic and cannot be used in preparative separations. In reversed phase chromatography of proteins the solvents acetonitrile, isopropanol or propanol are used widely. Mixtures of phosphoric acid and amines and perfluorinated carboxylic acids, especially trifluoroacetic acid (TFA), are popular as ionic modifiers to be added to the mobile phase. RPC techniques are reviewed in Kegruer's article in Science, 222/4621 (1983) pages 245-252. Use of hydrophobic acids, such as TFA, together with supports having surface silanols and solvents such as acetonitrile and propanol are discussed. While in analytical HPLC these solvents and buffer systems are acceptable, in preparative chromatography the solvents and ionic modifiers must be non-toxic and easily removed and some of the analytical reagents are not suitable for this reason. The mobile phase for use in preparative HPLC should be mild to the protein so as not to denature it and be inert to the support. Damage to the support is not only inherently disadvantageous in relation to the support itself but can produce toxic by-products which are not acceptable with proteins which might be used for, for example, pharmaceutical applications. It is an object of this invention to go some way towards avoiding these disadvantages or achieving these desiderata or at least to provide the public with a useful choice. It has now been found unexpectedly, that the selection of a physiological carboxylic acid of structure YCOOH where Y is a polar electron withdrawing group capable of hydrogen bonding silanol groups in a siliconaceous support, goes some way to achieving these desiderata . A preferred physiological carboxylic acid is a carboxylic acid which is present in vivo in a biochemical pathway such as the glycolytic pathway or the citric acid cycle. Not only are these acids of a natural origin and thus suitable in pharmaceutical applications, but unexpectedly these acids allow stabilisation of the native protein structure (so as to control the undesired interactions between the stationary phase and the solute) as well as allowing elution of the protein sample under milder chromatographic conditions. Because of the stabilisation of protein structure (and thereby limiting the number of hydrophobic contacts with the reversed phase) a lower concentration of organic solvent or a solvent of lower eluotrophic strength can be used to elute the protein molecule. Thus this invention allows the use of ethanol in a mobile phase with subsequent advantages in pharmaceutical applications. Ethanol is not sufficiently non-polar to elute protein samples which have a high number of non-polar interactions with the stationary phase. This invention also allows the use of a moderate pH value (between 2.2 and 5) in the mobile phase instead of the values of pH < 2.2 or pH > 5 which are currently used in reversed phase chromatography of proteins. The use of moderate pH values results in greater stability of both the protein sample and the stationary phase. Therefore the purified protein is recovered with higher biological activity and is not contaminated with C₁₈-silica or other degradation products caused by hydrolysis of the C₁₈-silica with either the high or low pH values. Another unexpected advantage of this invention is that the physiological carboxylic acid of structure YCOOH associates via hydrogen bonding interactions with silanol groups of the reversed phase column. These interactions result in a dynamic layer of physiological acid being associated with the underlying silica and thereby prevent a direct interaction between the ammonium groups of protein molecules and the silanol groups present in the reversed phase packing material. These undesired interactions have been associated with loss of protein materials by irreversible binding and with peak broadening and tailing with consequent losses of separation efficiency. Accordingly the invention may be said broadly to consist in a solution suitable for use as a mobile phase in preparative HPLC which comprises substantially pure water containing .005 to 1 molar of a physiologically acceptable carboxylic acid, the acid being of the general formula YCOOH wherein Y is a polar electron withdrawing group capable of hydrogen bonding silanol groups in a siliconaceous support, said solution also containing up to 95% by volume of a physiologically acceptable organic solvent. Preferably Y is H, X(CR₁R₂) n -, or a cyclic or heterocyclic ring compound substituted with hydroxy groups, wherein, X is -H, -OH, -COOH; R₁ and R₂ (which may be the same or different) are -H, -OH or -COOH, or -R₃COOH wherein R₃ is lower alkyl; and n is 0 or an integer from 1 to 5, provided that Y comprises at least one hydroxy or carboxy group. Preferably said carboxylic acid is any one of the following: malonic acid, citric acid, galacturonic acid or glucuronic acid. Preferably the solution contains a salt such as NaC1, KC1 or NH₄C1. Most preferably said carboxylic acid is citric acid. Preferably said organic solvent is ethanol. In another alternative the invention may be said broadly to consist in the recovery of proteins through the use of reversed phase HPLC using as a mobile phase a solution as defined herein above. Preferably the organic solvent of said solution is ethanol. Preferably said method includes the use of a support comprising silica with pendent hydrocarbon groups, such as octadecyl, alkylnitrile or alkylphenyl. Preferably said mobile phase contains 1% NaC1. Preferably said support is an organic copolymer, such as TSK-PW, which has good stability to moderate pressures (up to 2000 psi) and is compatible with polypeptide samples and having pendent hydrocarbon groups such as octadecyl, alkylnitrile or alkylphenyl. Preferably said support is suitable for hydrophobic interaction chromatography (HIC). More preferably said support is a silica - based or organic copolymer with a coating of a polar, neutral phase, such as a diol and a light coating of hydrophobic groups, such as butyl. Most preferably said support is C₁₈-silica, with a relatively light loading of hydrocarbon groups, e.g. 9-14% for a silica of 300 m²/g. Preferably the protein sample is isolated after the chromatographic separation by ultrafiltration or dialysis. Preferably the combination of a physiological carboxylic acid and organic solvent in the mobile phase was chosen so that a membrane of suitable pore size would permit passage of low molecular weight molecules present in the mobile phase but not a high molecular weight protein sample. The invention may be more fully understood by having reference to the accompanying drawings in which Figures 1-16 are chromatograms of the following substances and under the following conditions: Figure 1: COLUMN: Partisil 10 ODS (300 x 4 mm) Buffers: A) 0.1% citric acid in H₂O/2-Propanol (9:1) B) 0.1% citric acid in H₂O/2-Propanol (1:9) Linear gradient from 0 to 100% in 1 hr at 1 mi/min. Detector: Waters Model 450 variable wavelength detector at 220 nm. A 2.0 CHART: 200 mm/hr Insulin (porcine) retention time = 17-18 min Albumin (bovine) retention time = 25-27 min Figure 2: COLUMN: Rad-Pak-C₁₈ Buffers: (as in Fig 1) Linear gradient from 0 to 100% in 1 hr at ml/min. Detection: 280 nm A 0.1 Chart: 200 mm/hr Albumin (bovine) β-lactoglobulin A) β-lactoglobulin B) not separated Figure 3a: Instrument: Prep/LC-500 (Waters) Column: Prep-Pak-C₁₈ (1 cartridge) Buffers: A) 0.1% citric acid in H₂O/95% EtOH (9:1) 3 litres B) 0.1% citric acid in H₂O/95% EtOH (1:9) 3 litres Gradient concave at 50 ml/min Detection: 280 nm; A 1.0 and 2.0 (see chart) CHART: 200 mm/hr 1.0 g of insulin (porcine; Nordisk) retention time 65 min. Figure 3b: Insulin after chromatography on the Prep/LC-500 (see 3a) Column: Rad-Pak-C₁₈ Buffers: A) 0.1% citric acid in H₂O/2-Propanol (9:1) B) 0.1% citric acid in H₂O/2-Propanol (1:9) Gradient: linear from 0 to 100% at 1 ml/min in 1 hr Detection: 220 nm A 2.0 125 µg of insulin. Retention time 23 min. Figure 4: Instrument: Prep/LC-500 Waters. 1.0 g bovine serum albumin (BSA) COLUMN: Prep-Pak-C₁₈ (1 cartridge) Buffers: A) 0.1% citric acid in H₂O/95% EtOH (9:1) 2 litres B) 0.1% citric acid in H₂O/95% EtOH (1:9) 3 litres Gradient: concave at 50 ml/min Detection: 280 nm A 2.0 Chart: 200 mm/hr Retention time 85 min (top of peak) Figure 5: COLUMN: Rad-Pak-C₁₈ Buffers: A) 0.1% citric acid in H₂O/2-Propanol (9:1) B) 0.1% citric acid in H₂O/2-Propanol (1:9) Detection: 220 nm Insulin (porcine: Nordisk) 50 µg Albumin (bovine: Sigma) 50 µg β-Lactoglobulin A 50 µg β-Lactoglobulin B 50 µg Detection: 280 nm A 2.0 Chart: 200 mm/hr Figure 6: Conditions as in Figure 5 β-Lactoglobulin A 50 µg β-Lactoglobulin B 50 µg Detection: 280 nm A 2.0 Chart: 100 mm/hr Gradient: Linear from 25 to 50% in 1 hr at 0.5 ml/min Figure 7: Conditions as in Figure 6 100 µg of whey protein Figure 8a: The separation of human growth hormone, Nordisk Insulin Laboratories. Conditions as in Figure 5. GRADIENT: Linear 25 to 100% in 1.5 hr at 0.5 ml/min. Figure 8b: The separation of human growth hormone, New Zealand National Hormone Laboratory. Conditions as in Figure 5. GRADIENT: Linear 25 to 50% in 1 hr at 0.5 ml/min. Figure 9: Coating of the column with acid. Column: Waters; 8 MBC1810 µ, P4194A01 Solvent: water/2-propanol 9:1 Injections (repeated) of 1% (v/v) citric acid. (20 µl) Detection: Differential Refractometer R401 Sensitivity X 2. Figure 10: Column: Waters; 8NVC18 5 µ, P4136D01 Solvent: water/2-propanol 9:1 Injection of 1% citric acid (20 µl) Detection: R 401 sensitivity X 1 Figure 11: Shows a test mixture of proteins on 8 different columns. Column A: SUPELCO : LC-3DP B: WATERS : 8MBC1810 µ C: SUPELCO : LC-318 D: WATERS : NOVAPAK-C18 E: WATERS : 8NVC185 µ F: VYDAC : PROTEIN-C4 G: WHATMAN : PROTESIL-300 OCTYL-25 H: SYNCHROM.INC : SYNCHROPAK RP-P Buffer: citric acid/salt system Program : Linear gradient usually from 15-100% B in 1 hour at 1 ml/min. Sample : peak 1 : insulin (porcine) 2 : cytochrome C. (horse heart) 3 : bovine serum albumin 4 : α- lactalbumin 5(+8):myoglobin (equine skeletal muscle) 6 : β- lactoglobulin B 7.: β- lactoglobulin A Figure 12: Separation of whey proteins. Mixture containing: peak 4 : α- lactalbumin 6 : β- lactoglobulin B 7 : β- lactoglobulin A Columns: A VYDAC : C4 B SUPELCO : LC-318 C SUPELCO : LC-3DP D SYNCHROM. INC. : SYNCHROPAK RP-P Buffer : citric acid system Program : linear gradient from 25-50% B in 1 hour at 1 ml/min Figure 13: Separation of insulins. Buffer : citric acid system Program : linear gradient from 13-20% B (column A) linear gradient from 15-25% B (others) in 1 hour at 1 ml/min Sample : peak A) equine insulin B) bovine insulin C) porcine insulin Columns used: A SUPELCO : LC-3DP B SUPELCO : LC-318 C VYDAC : PROTEIN-C₄ D PROTESIL - 300 OCTYL-25 Figure 14: Preparative chromatography of 1.0 g of bovine serum albumin. Instrument: Prep - 500 Waters Column: 1 C18 - cartridge Buffers : A : 0.1% citric acid + 1% NaC1 in H₂O/95% EtOH 3:1 Buffer B :0.1% citric acid + 1% NaC1 in H₂O/95% EtOH 45:55 Gradient was concave and was made up from 1 1 buffer A and 5 l buffer B. Figures 15(a-c): On the Supelco LC-318 column was injected the general test mixture described before. Buffers: Figure 15a: A : 0.1% citric acid + 1% salt in H₂O/IPA 9:1 B : 0.1% citric acid + 1% salt in H₂O/IPA 1:4 Figure 15b: A : 0.1% v/v H₃PO₄ + 1% salt in H₂O/IPA 9:1 B : 0.1% v/v H₃PO₄ + 1% salt in H₂O/IPA 1:4 Figure 15c: A : 0.1% TFA + 1% salt in H₂O/IPA 9:1 B : 0.1% TFA + 1% salt in H₂O/IPA 1:4 Linear gradients from 15-60% in 1 hour at 1 ml/min for A and B. From 5-60% B in 1 hour 1 ml/min for C. Figure 16: On the Supelco LC-318 column was injected a mixture of: (a) equine insulin (b) bovine insulin (c) porcine insulin Buffers as in Figure 15a Gradients: A and B from 15-25% B in 1 hour; 1 ml/min C from 10-25% B in 1 hour; 1 ml/min Figure 17: On a Synchroprep column was injected: A. Human Serum Albumin (HSA) B. Bovine Serum Albumin (BSA) C. Porcine Insulin. Other parameters are set out in Example 11. Figure 18: On the columns listed a general protein mixture was injected. Other parameters are set out in Example 12. Figure 19: As in figure 18 except insulins were injected as exemplified in Example 12. Figure 20: As in figure 18 except whey proteins were injected as exemplified in Example 12. HPLC was carried out according to the techniques described in the following references: 1. Journal of Chromatography 192 (1980) 222-227. 2. Journal of Liquid Chromatography 4,661-680 (1981). 3. Journal of Chromatography 249 (1982) 193-198. In addition to the C₁₈-silica columns used in these papers it is also possible to use, for example, alkylphenyl or C₈ columns. In examples 1 and 2 insulin and serum albumin were examined as examples of small and large proteins respectively. The separation of albumin was found to be much more demanding than insulin. Only the superior eluotrophic properties of the ionic modifiers of the formula YCOOH allowed good recovery and separation of albumin in the presence of ethanol-water mixtures. Example 8 shows that the nature of the gradient of organic solvent is important. EXAMPLE 1 : Testing of Buffer Systems Gradient systems were set up starting with water/isopropanol 9:1 and ending at 1:9 to which was added 0.1% acid (Tables 1 and 2). Compounds marked with ++ did not only allow elution of the protein but the peak shape and recoveries were good. The gradient was delivered by two Waters HPLC pumps Model 6000 A in combination with a Model 660 solvent programmer. Detection: Waters Model 450 Variable Wavelength Detector at 220 mm and 2.0 Aufs. Column: C₁₈-Radial Pak, 8mm i.d. (8MBC1810 µ; P3171D02 Buffer A: 0.1% reagent in water/isopropanol 9:1 Buffer B: 0.1% reagent in water/isopropanol 1:9 Solvents were freshly prepared and filtered through Millipore filters. (0.45 µm). 100 µg of bovine albumin (Sigma, No. A-4503) was injected in a linear gradient run from Buffer A to B in one hour at 1.0 ml/min. The strong inorganic acids, hydrochloric and sulphuric were tested in a different way using small glass columns filled with C₁₈-silica (37-75 µ ). Albumin was eluted but damage to the columns was evident, as shown by the elution of the waxy C₁₈-column coating. EXAMPLE 2 : Preparative Scale Purification of Albumin (citric acid) Instrument: Prep LC/System 500 A (Waters) Detection: Model 550 A Variable Wavelength Detector at 280 nm; A 2.0 (Waters) Column: 1 C₁₈-silica cartridge Buffer A: 0.1% citric acid in water/95% ethanol 9:1 (2.2 1) Buffer B: 0.1% citric acid in water/95% ethanol 1:9 (3 1) The concave gradient was obtained by a simple mixing flask containing buffer A. This flask is closed with a rubber bung through which one "TEFLON" (a trade mark) tube leads to the chromatograph, the other to buffer B. Buffer B automatically flows into this mixing flask when the pump is running. The albumin sample (1.0 gram) is dissolved in 200 ml of water and pumped onto the column, the system is washed with 200 ml of buffer A after which the gradient is started. Albumin is eluted after about 1.5 l of buffer has been used and at this moment the ratio of alcohol/water is approximately 1:1 (Figure 3a). Working Up Procedure The albumin solution obtained above is diluted to about 20% alcohol and subjected to ultrafiltration. By this technique the buffer components are removed. Subsequently the albumin may be freeze dried to a colourless powder. Alternatively, the albumin solution can be adjusted to a desirable buffer composition for direct use. EXAMPLE 3 : Preparation of Semi-Purified Insulin Insulin may be treated by the method set out in example 2 of United Kingdom Patent Specification No. 1,285,024 except that the ion exchanger to be used is "INDION-QAE" (trade mark). This is a strongly basic ion exchanger whose functional group is quaternary amine and whose counter ion is chloride It is a cross-linked hydrophilic matrix derived from regenerated cellulose. "INDION-QAE" is a registered trade mark of Phoenix Chemicals Limited, C/o Waitaki NZ Refrigerating Limited, P.O. Box 1472, Christchurch, New Zealand. EXAMPLE 4 : Other Separations of Proteins In general, a gradient was used from initial buffer A (0.1% citric acid in water and 2-propanol ratio 9:1) to buffer B (0.1% citric acid in water and 2-propanol-ratio 1:9). Note : In these examples the citric acid concentration is constant throughout the gradient. The results of these separations are shown in the accompanying drawings as discussed below. Figures 1 and 2 show separation of porcine insulin from bovine albumin and albumin from β-lactoglobulin A and B respectively. Figure 3a shows a preparative chromatography run (Prep. 500) of porcine insulin (1 gram) with citric acid - ethanol system (see example 1). Figure 3b is the analytical chromatogram of the preparative run in 3a. A similar chromatogram is shown in Figure 4, a preparative run for bovine albumin. Figure 5 shows a combination of Figures 1 and 2 and illustrates excellent separation of insulin, albumin and β-lactoglobulin A and B. Figure 6 illustrates that fine tuning leads to separation of the β-lactoglobulins. Figure 7 shows clear separation of whey protein components. Figure 8a shows how a commercial sample of human growth (HGH) can be clearly separated from several very minor contaminants. Figure 8b illustrates a sample of HGH from a source in New Zealand. EXAMPLE 5 : COATING OF THE COLUMN WITH ACID ADDED TO MOBILE PHASE In passing a buffer system through a column it is assumed that part of the buffer components are "bound" to the column. This could be permanently or in a dynamic equilibrium. It is believed that the binding of the buffer to the reversed phase column results in the deactivation of silanol groups with the consequent improvement in the chromatography of proteins. The occurrence of this interaction is demonstrated in a new Rad Pak-C₁₈ column (Waters; 8MBC1810µ, P4194A01) which was washed with methanol and 80% isopropanol and a gradient set up to 10% isopropanol. In an isocratic system using 10% isopropanol/water 20 µl of a 1% solution of citric acid dissolved in the same solvent was injected repeatedly. The peak (detection RI) was trapped and the sample titrated with 0.01M sodium hydroxide. On the first injection the acid peak was wider than in all following injections (see Figure 9 and Table 3). A small quantity of the acid had been bound to the column. Normally titration of the peak took 0.80 ml of sodium hydroxide. For the first peak however 0.60 ml was needed. It seems that a certain amount of acid is bound during the first injection (equivalent of ∼1-2 µMol) also the peak shape shows that interaction between the column and the citric acid has occurred. The fact that after thorough washing, the column absorbed a similar amount of acid again on repeating the experiment suggests that much of the acid is not irreversibly bound to the column but is in a dynamic equilibrium with it. With another column, NovaPak-C₁₈ (Waters; 8NVC18 5µ :P4136DO1), the experiment was repeated. Again we observed the phenomenon described above (Figure 10). EXAMPLE 6 : RECOVERY OF PROTEINS FROM THE REVERSED PHASE COLUMN The recovery of a protein from a column depends strongly on the way the chromatographic process is carried out. If bovine serum Albumin (BSA) is injected at 0% organic solvent and a linear gradient run up to 80 or more % organic solvent, the BSA is usually eluted at about 50% organic. The recovery can be very small even down to 10%. If however BSA is injected at a higher level of organic solvent (25%) and the gradient started, it will elute at a lower percentage of organic solvent than mentioned before and the recovery improves considerably and may reach 95% or more. To ensure the best possible separation and recovery the following scheme can be used: 1) Find out the maximum percentage of organic solvent in which the protein shows retention in 5% steps. For example, if BSA shows no retention at all in 30% organic then start the chromatography at 25%. 2) Set up a shallow gradient up to the lowest possible percentage of organic solvent that will elute the protein(s). Examples: A) Separation of bovine and porcine insulin. Usually run in 1 hr from 15-25% buffer B (containing 0.1% acid + 1% salt in water/isopropanol 1:4). B) Separation of α-lactalbumin, β-lactoglobulin A and B. Usually run from 25-50% buffer B in 1 hour. If a mixture of proteins with wide ranging polarities is injected the recoveries may vary considerably, unless the selection of the mobile phase and gradient condition is carefully made. EXAMPLE 7 : COMPARISON OF DIFFERENT COLUMNS FOR PROTEIN SEPARATION From the results of the twenty analytical columns tested with different solvent systems, it is clear that only the very wide pore packings are suitable for high MW protein separations. (See Table 4 for column parameters). In general the best separations are obtained on the Supelco LC-318 and Vydac C-4 columns (both 300 Å). A column that performs very well for the chromatography of the different insulins (Water Assoc. NOVAPAK C18) is less successful with the bigger proteins like BSA, because of its small pores 10 nm (approx. 100 Å). The 250 mm columns like the Whatman Protesil - 300 OCTYL25 and Synchropak RP-P (CR 103-25) give rise to fairly high backpressures and are therefore not ideal with solvent systems of high viscosity. In conclusion it may be said that an ideal column for analytical protein separations in the systems described is short (50 or at the most 100mm long) and has a pore size of approximately 30 nm (300 Å). For preparative liquid chromatography of proteins longer columns will be needed but since they will also be wider no problems are expected with back pressures. A) General protein separation (Figure 11 citric acid) Normally a mixture was injected containing: B) Separation of β-lactoglobulin A and B (Figure 12 citric acid) A mixture of proteins isolated from whey was injected containing: C) Separation of different insulins (Figure 13 citric acid) A mixture of bovine and porcine insulin was used to test the columns. When the separation was very good also equine insulin was injected. peak a) equine insulin A chain Ala₈-Ser-Val b) bovine insulin A chain Thr₈-Ser-lle c) porcine insulin A chain Thr₈-Gly-lle EXAMPLE 8 : PREPARATIVE CHROMATOGRAPHY OF 1.0 GRAM OF BOVINE SERUM ALBUMIN (citric acid + salt) Instrument: Prep LC/System 500A (Waters) Detection: 280 nm A 2.0 Buffer A: 0.1% citric acid + 1% NaCl in H₂O/95% - EtOH 75:25 Buffer B: 0.1% citric acid + 1% NaCl in H₂O/95% - EtOH 45:55 1.0g of BSA dissolved in 200 ml buffer A was pumped onto the column (1 column C18 - silica 250 x 50 mm, Waters) followed by another 100 ml of buffer A. A concave gradient was now started using a 1 l of buffer A and 5 l of buffer B. The peak was trapped in several fractions. (Figure 14). Recovery 98-100% EXAMPLE 9 : COMPARISON OF CITRIC ACID WITH PHOSPHORIC ACID AND TRIFLUOROACETIC ACID In a final number of experiments we have compared the systems of this invention with the known phosphoric acid and TFA systems. In Figures 15 and 16 it is demonstrated that the weaker acid gives more resolution then the stronger acid or in other words the resolving power of citric acid>phosphoric acid>TFA. EXAMPLE 10 : AUTOMATED PREPARATIVE CHROMATOGRAPHY OF PROTEINS ON WIDE PORE C-18 SILICA Column A column was packed with Synchroprep a C18-silica, spherical, 30 with 300 A pores. Column dimensions 250 x 10 mm 0. A number of automatic purifications of proteins were carried out. Buffers (A) 0.1% citric acid + 1% sodium chloride in water/95% -ethanol 9:1 (B) 0.1% citric acid + 1% sodium chloride in water/95% -ethanol 1:4 EXAMPLE 10A : HUMAN SERUM ALBUMIN Repeatedly charges of 50 mg of HSA were injected and a linear gradient started from 45 to 55% B over 20 minutes at 1.5 ml/min. The first peak is a mixture of citric acid added to the sample and N-acetyltryptophan, present in the sample as a stabiliser. The second peak is albumin. Arrows indicate where trapping was started and ended. After 30 minutes the buffer mixture was changed back to initial conditions. (The difference between starting and final conditions is small enough that this can be done without running a gradient). For 10 minutes the column was run at initial conditions, then a new sample injected and the gradient started 2 minutes later. EXAMPLE 10B : BOVINE SERUM ALBUMIN BSA (40 mg) was injected repeatedly. The procedure was as in example 11A but the gradient used was from 50-60% B at 1.5 ml/min in 15 minutes. An abrupt change to initial conditions was possible after 30 minutes. After a number of runs a gradient was run up to 100% B to clean the column (fraction B). EXAMPLE 10C : BOVINE INSULIN An isocratic system was employed at 45% B which made gradients unnecessary. Figure 17B shows a simulated automatic run where insulin was injected every 36 minutes. In this run the quantities injected were increased from 5 mg (run not shown) up to 40 mg (peak III). Later a gradient was run up to 100% B to clean the column whereby Peak B was eluted (not identified). CHROMATOGRAMS : See Figure 17 Sample Preparation Retention times of the proteins are influenced when relatively large quantities are injected. Preferably the proteins are dissolved in the same solvent in which the column is equilibrated. In the case of insulin this is possible if enough solid citric acid is added to the mixture. In the case of the albumins this was not possible. To dissolve albumin in a high concentration 20 or 25 mg/ml in a solvent containing 45 or 50% 95% ethanol is not possible. However a smaller amount of isopropanol can replace the ethanol without significantly altering the polarity of the sample solvent. Human Serum Albumin 1 ml of albumin (a 25% solution of HSA) was diluted with 7 ml of buffer A, then 2 ml of isopropanol added and solid citric acid to pH 3.0. Bovine Serum Albumin BSA (200mg, Sigma) was dissolved in 8 ml buffer A, 2 ml of isopropanol added and solid citric acid to pH3.0. Insulin (Porcine) Insulin (200mg Nordisk) was suspended in 10 ml of a mixture of 45% buffer B and 55% buffer A. Solid citric acid was added until all insulin was dissolved. EXAMPLE 11 : SEPARATION OF PROTEINS USING MALONIC ACID GLUCURONIC ACID AND FORMIC ACID Reversed phase columns used for this work were the Supelco LC-318 and the Vydac Protein-C4 as examples of wide pore (300A) columns and the Waters Novapak C18 and 8NVC18 5 µ as examples of narrow pore C18-silicas. The buffer systems were: Buffer A: 0.1% acid + 1% NaCl in water/isopropanol 9:1 Buffer B: 0.1% acid + 1% NaCl in water/isopropanol 1:4 Samples (1) (Fig 18) The general protein mixture described in relation to Figure 11. (2) (Fig 19) The mixture of whey proteins described in relation to Figure 12. (3) (Fig 20) Insulins; equine, bovine and porcine. Results (a) As demonstrated before the wide pore columns are superior for protein work. (b) The resolution improves when the acid is weaker or in other words, formic acid is better than glucuronic, glucuronic is better than malonic. (c) Careful comparison of these results with those obtained with citric acid shows that formic acid is certainly a good acid for this work coming close to the resolving power of citric acid. From a health point of view, formic acid however may not be used for preparative h.p.l.c. of proteins to be used in medicine. EXAMPLE 12 : SALTS IN BUFFER It has been shown in many of the previous examples that the addition of from about 0.5 to 2.0% salt enhanced the resolution. Satisfactory salts are set out in Table 5. Instead of salts, neutral, non-ionic compounds were added to the mobile phase. For example, urea, glucose and glycerol were tried but did not produce useful separations.

Claims: A mobile phase for use in the purification of proteins using reversed phase HPLC on a preparative scale, the mobile phase being characterised in that it comprises substantially pure water containing .005 to l molar of a physiologically acceptable carboxylic acid, the acid being of the general formula YCOOH wherein Y is a polar electron withdrawing group capable of hydrogen bonding silanol groups in a siliconaceous support, said solution also containing up to 95% by volume of a physiologically acceptable organic solvent. A mobile phase as claimed in claim l wherein Y is X(CR₁R₂) n -, or a cyclic or heterocyclic ring compound substituted with hydroxy groups, wherein, X is -H, -OH or -COOH; R₁ and R₂ (which may be the same or different) are each -H, -OH, -COOH, or -R₃COOH wherein R₃ is lower alkyl; and n is 0 or an integer from l to 5, provided that Y comprises at least one hydroxy or carboxy group. A mobile phase as claimed in claim l or claim 2 wherein said carboxylic acid is selected from malonic acid, citric acid, galacturonic acid and glucuronic acid. A mobile phase as claimed in any one of claims l to 3 wherein said solution contains a salt selected from NaCl, KCl and NH₄C1. A mobile phase as claimed in any one of claims l to 3 wherein said carboxylic acid is citric acid. A mobile phase as claimed in any one of claims l to 5 wherein said organic solvent is ethanol. A method of purifying on a preparative scale a protein from a mixture of proteins by reversed phase HPLC which comprises the steps of: providing a column packed with an HPLC support of sufficient porosity to allow passage of proteins, introducing a protein mixture into the end of said column, and eluting said column with a mobile phase as claimed in any one of claims l to 6. A method as claimed in claim 7 which includes the subsequent step of isolating said protein by ultrafiltration or dialysis.

Inventors: HANCOCK, WILLIAM STEPHAN, HARDING, DAVID ROGER KAY, POLL, DICK JACOB
Applicants: MASSEY UNIVERSITY
Application year: 1986
Main classification: C07K3
IPC codes: B01D15, G01N30, C07K1